Recent Finacing
Recent Raise
Advanced BioDesign develops targeted therapies for resistant cancers, advancing ABD‑3001—a first‑in‑class ALDH1/3 suicide inhibitor that induces cancer cell apoptosis while sparing healthy cells; lead indication AML, preclinical.
